{"id":208856,"name":"END SUD, INC. DBA END SUBSTANCE USE DISORDER","slug":"end-sud-inc-dba-end-substance-use-disorder","state":"TX","country":"United States of America","description":"","totalSpending":270000,"filings":10,"yearlySpending":[{"year":2021,"income":200000},{"year":2022,"income":70000}],"issues":["ALC","MMM"],"firms":["END SUD, INC. DBA END SUBSTANCE USE DISORDER"],"lobbyists":["ERIN SCHANNING","KRISTINA TRAVIS"],"govEntities":["Executive Office of the President (EOP)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Office of Natl Drug Control Policy (NDCP)","Substance Abuse & Mental Health Services Administration (SAMHSA)","Drug Enforcement Administration (DEA)","Justice, Dept of (DOJ)"],"sampleDescriptions":["Mainstreaming Addiction Treatment Act (H.R. 1384, S. 445) and policies to end substance use disorder.","H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOI","H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOI","H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.\n\nU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIO","H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.\n\nU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIO"],"years":[2021,2022]}